| Similar Articles |
|---|
 |
The Motley Fool
October 18, 2010
Travis Hoium |
Lexicon Pharmaceuticals Shares Popped: What You Need to Know Lexicon Pharmaceuticals shares jumped 10% in early trading Monday on unusually high trading.   |
The Motley Fool
November 10, 2011
Dan Caplinger |
Has Savient Pharmaceuticals Become the Perfect Stock? For Savient to get closer to perfection, it simply has to do one thing: Make Krystexxa the success story it seemed to be last year. |
The Motley Fool
September 15, 2010
Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer. |
The Motley Fool
October 12, 2010
Travis Hoium |
King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc. |
The Motley Fool
June 17, 2009
Brian Orelli |
Savient Saves and Moves Up The FDA advisory panel gives Savient's Krystexxa a passing grade. |
The Motley Fool
October 26, 2010
Travis Hoium |
ARIAD Pharmaceuticals Shares Plunged: What You Need to Know A day after shares pop, the company announced a stock offering at $3.70 per share, and shares drop. |
The Motley Fool
January 3, 2011
Travis Hoium |
Inspire Pharmaceuticals Shares Plunged: What You Need to Know The new trading year came in with a loud thud for Inspire Pharmaceuticals when its stock fell 58% this morning. |
The Motley Fool
July 19, 2011
Anand Chokkavelu |
7 Biotechs Near 52-Week Lows Here are the largest seven companies in biotech stocks that are within 20% of their 52-week lows. |
The Motley Fool
August 3, 2009
Brian Orelli |
The Roller-Coaster Stock That Keeps on Giving Savient's gout treatment isn't approved just yet. |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares. |
BusinessWeek
November 4, 2010 |
Big Deals in Unlikely Places These are the largest emerging-market telecommunications mergers announced in 2010. Only the Telefonica deal involved a major Western buyer. |
The Motley Fool
May 22, 2007
Mike Havrilla |
Savient Seems Set for a Success With generic competition against one drug, the company is ready to produce another. Biotech investors are encouraged to take a look here. |
The Motley Fool
December 27, 2010
Brian Orelli |
FDA Kicks Dust on Alimera's Fairy Tale Eight months after its IPO, Alimera gets hammered. |
PHONE+
Weldon Long |
Effective Questioning Combats Centuries-Old Selling Problem The author explains how effective questioning can direct the sales process to a successful conclusion for both the buyer and the seller. |
The Motley Fool
May 5, 2005
Marko Djuranovic |
Shake That Seller's Mindset Stock price quotes are geared toward those looking to sell, but it's best to avoid that mindset. Instead, think like a buyer. |
The Motley Fool
January 5, 2012
David Williamson |
Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%. |
Investment Advisor
October 2007
Joni Youngwirth |
It's Not All Gold No doubt, buying a practice is a good way to grow if you find a firm that is right for you. But unless you do, don't be sucked into the buying frenzy. |
Registered Rep.
February 25, 2013
Furey & Cooper |
What Is Your Advisory Practice Really Worth? The perils of the valuation gap. |
The Motley Fool
October 23, 2007
Mary Dalrymple |
Protect Yourself Amid the Mortgage Mess Even without the additional worries surrounding the mortgage industry, home buying can be a complicated business that requires a fair amount of legal expertise. Using a buyer's agent can give you some protection. |
BusinessWeek
September 1, 2009
Catherine Arnst |
Opportunities in the Obesity Epidemic Drugmakers are ratcheting up research into treatments for gout and other ills that plague the overweight. |
Financial Planning
January 1, 2006
Glenn G. Kautt |
Factors 1-2-3 Fama and French's famous model explains variances in stock prices -- but another three-factor model explains major changes in the value of your firm. |
The Motley Fool
January 4, 2012
Rebecca Lipman |
Biotech Ideas: Top Biotech Stocks with Bullish Institutional Trends "Smart money" investors are feeling bullish about these biotech companies: Amyris... VIVUS... InterMune... Savient Pharmaceuticals... Bacterin International... Seattle Generics... Oncothyreon... |
The Motley Fool
April 24, 2007
Jim Gillies |
Options: The Basics Options aren't terribly difficult to understand. Calls are the right to buy, and puts are the right to sell. Here's how to use them appropriately in your own portfolio. |
Financial Planning
February 1, 2005
David Grau |
Research Assignment When buying or selling a financial advisory firm, due diligence may be the most important thing you do before signing on the dotted line. |
Inc.
September 2006
Elaine Appleton Grant |
Hush Money For sale: a manufacturer of sound isolation booths and acoustics products in southern Oregon. |
